It is Veriton Pharma’s policy to conduct all of our business in an honest and ethical manner. We take a zero-tolerance approach to bribery and corruption, and we are committed to acting professionally, fairly and with integrity in all our business dealings and relationships.
We expect all individuals working for us or on our behalf in any capacity to uphold the spirit of our policy.
Our full Anti-Corruption and Bribery policy can be found here.
We are committed to developing licensed medicinal products that meet the specific needs of our patients. Veriton Pharma’s portfolio of prescription medicines stems from our team’s deep expertise in the field of epilepsy.
Young Epilepsy and Veriton Pharma Ltd (Veriton) have announced a key agreement, where the organisations will work in partnership to deliver the ‘Rules 4 Schools” element of the charity’s newly… Read More
Epistatus is licensed for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy1. Epistatus… Read More
2nd October 2017: Weybridge, UK: Today, Veriton Pharma Ltd is announced as the new company name for Special Products Ltd. This name change has occurred both to incorporate the company’s… Read More
8th September 2017: Special Products Ltd is pleased to announce that Epistatus® 10 mg Oromucosal Solution, Midazolam, is now available to prescribe. The NHS price for a single 10mg in… Read More